구독하기
연구 모델
서비스
전임상 효능 평가
Resource
huIL4/huIL4RA Mouse
제품 견적 요청
카탈로그에서 제품을 선택하여 요청을 제출해 주세요. Cyagen 팀이 상세 정보를 제공해 드립니다.
huIL4/huIL4RA Mouse
제품명
huIL4/huIL4RA Mouse
제품 ID
C001834
품종 계통
C57BL/6NCya-Il4em1(hIL4)Il4raem1(hIL4R)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huIL4/huIL4RA Mouse (카탈로그 번호 C001834)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
Immune Target Humanized Mouse Models
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
가격 문의
HUGO-GT Humanized Models
Tumor Target Humanized Mouse Models
Immune Target Humanized Mouse Models
기본 정보
검증 데이터
관련 자료
기본 정보
유전자 별칭
BSF1, IL-4, BCGF1, BSF-1, BCGF-1, CD124, IL4RA, IL-4RA
염색체
Chr 5, Chr 16
MGI ID
Datasheet
품종 계통 설명
Interleukin-4 (IL-4) and its receptor, IL-4R, are pivotal regulators of immune responses and inflammation. The IL4 gene encodes the IL-4 cytokine, a multifunctional protein predominantly secreted by Th2 cells, mast cells, and eosinophils, while the IL4R gene encodes the IL-4 receptor, which is expressed on a variety of immune cells, including B cells, T cells, macrophages, and endothelial cells. IL-4 binds to IL-4R, which exists in two distinct forms: Type I (comprising IL-4Rα and the common γ-chain) and Type II (comprising IL-4Rα and IL-13Rα1) [1]. This interaction activates the JAK-STAT signaling pathway, driving Th2 cell differentiation, B cell class switching to IgE, and anti-inflammatory responses. The IL-4/IL-4R signaling axis is critically implicated in allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis, as well as in parasitic infections and certain cancers [2-5]. Dysregulation of this pathway underlies various pathological conditions, positioning IL-4Rα as a promising therapeutic target. For instance, dupilumab, a monoclonal antibody targeting IL-4Rα, has been approved for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, underscoring the therapeutic potential of modulating this pathway [6-7].
The huIL4/huIL4RA mouse model is generated by crossing IL4 humanized mice (Catalog Number: C001628) with IL4R humanized mice (Catalog Number: C001629), resulting in a dual-humanized model. This model faithfully recapitulates the human IL-4/IL-4R signaling pathway, making it an invaluable tool for studying allergic diseases (e.g., asthma and atopic dermatitis), Th2 immune responses, parasitic infections, tumor immunology, and chronic inflammation. Furthermore, it serves as a robust preclinical platform for evaluating the efficacy and mechanisms of therapeutic agents targeting the IL-4/IL-4Rα pathway.
Reference
Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016 Jan;15(1):35-50.
Oetjen LK, Mack MR, Feng J, Whelan TM, Niu H, Guo CJ, Chen S, Trier AM, Xu AZ, Tripathi SV, Luo J, Gao X, Yang L, Hamilton SL, Wang PL, Brestoff JR, Council ML, Brasington R, Schaffer A, Brombacher F, Hsieh CS, Gereau RW 4th, Miller MJ, Chen ZF, Hu H, Davidson S, Liu Q, Kim BS. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. Cell. 2017 Sep 21;171(1):217-228.e13.
Bankaitis KV, Fingleton B. Targeting IL4/IL4R for the treatment of epithelial cancer metastasis. Clin Exp Metastasis. 2015 Dec;32(8):847-56.
Davoodi P, Mahesh PA, Holla AD, Ramachandra NB. A preliminary study on the association of single nucleotide polymorphisms of interleukin 4 (IL4), IL13, IL4 receptor alpha (IL4Rα) & Toll-like receptor 4 (TLR4) genes with asthma in Indian adults. Indian J Med Res. 2015 Dec;142(6):675-80.
Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P. TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med. 2015 Aug 19;7(301):301ra129.
Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: A Review of Present Indications and Off-Label Uses. J Investig Allergol Clin Immunol. 2022 Apr 19;32(2):97-115.
Napolitano M, Ruggiero A, Patruno C. Dupilumab-associated inflammatory arthritis: a literature review. Clin Exp Dermatol. 2024 Mar 21;49(4):307-312.
변형 전략

Figure 1. huIL4 Mice Strategy. The sequences from the start codon to the stop codon of the endogenous mouse Il4 gene were replaced with the sequences from the start codon to the stop codon of the human IL4 gene.

Figure 2. huIL4RA Mice Strategy. The extracellular domain of the mouse Il4ra was replaced with the corresponding human IL4R extracellular domain, while retaining the murine signal peptide.
응용 분야
Investigation of immune regulation and Th2 responses, allergic diseases, parasitic infections, and tumor immunology;
Preclinical development, screening, and efficacy evaluation of IL4/IL4R-targeted therapeutic agents;
Studies on inflammation and autoimmune diseases.
검증 데이터
1. Gene Expression (RT-qPCR)
Transcript levels of hIL4, hIL4RA, mIl4, and mIl4ra were analyzed in the spleen and thymus of huIL4/huIL4RA and wild-type (WT) mice using species-specific primers. mβ-actin was used as the internal reference gene, and the relative expression level of each gene in each tissue was calculated. Data are presented as mean±SD. hIL4 and hIL4RA transcripts were detected in the spleen and thymus of huIL4/huIL4RA mice, whereas mIl4 and mIl4ra transcripts were not detected. In contrast, mIl4 and mIl4ra transcripts were detected in the spleen and thymus of WT mice, whereas hIL4 and hIL4RA transcripts were not detected.

Figure 3. RT-qPCR analysis of human IL4 and IL4RA transcripts and mouse Il4 and Il4ra transcripts in huIL4/huIL4RA and wild-type (WT) mice (8–9 weeks old, homozygous, female, n=4).
2. IL4RA Protein Expression (FACS)
Splenocytes were isolated from homozygous huIL4/huIL4RA and wild-type (WT) mice under basal or anti-mCD3ε-stimulated conditions to evaluate hIL4RA and mIL4RA protein levels using specific antibodies. Under basal conditions, hIL4RA was detected in splenic B cells of huIL4/huIL4RA mice but not in WT mice. Following anti-mCD3ε stimulation, the proportion of hIL4RA-positive B cells increased in huIL4/huIL4RA mice, with no mIL4RA detected. Conversely, WT mice expressed only mIL4RA, with no hIL4RA signal observed.

Figure 4. Flow cytometric analysis of human and mouse IL4RA protein expression in splenic B cells of huIL4/huIL4RA and wild-type (WT) mice. (7–9-week-old female homozygous mice, n ≥ 4).
3. IL-4 Protein Expression in the OXA-induced Atopic Dermatitis Model (ELISA)
(A) Schematic of the experimental procedure. Six-week-old female mice (n=3) were sensitized with a high dose of oxazolone (OXA) on Day 0, followed by repeated low-dose OXA ear challenges from Day 7 to 25. Mice were sacrificed on Day 26. Ear tissues were collected, snap-frozen, and homogenized to measure mouse and human IL-4 protein levels via ELISA.
(B) Mouse IL-4 protein was detected in the ear tissues of wild-type (WT) mice but not in huIL4/huIL4RA mice, confirming successful replacement of the endogenous mouse Il4 gene.
(C) Human IL-4 protein was detected in the ear tissues of huIL4/huIL4RA mice but not in WT mice, demonstrating that the human IL4 gene is functionally expressed under OXA-induced inflammatory conditions.

Figure 5. ELISA quantification of human and mouse IL-4 protein levels in ear tissues of huIL4/huIL4RA and wild-type (WT) mice in the OXA-induced atopic dermatitis model (6-week-old female homozygous mice, n=3. Data are presented as mean±SD).
4. Pharmacodynamics (PD) evaluation of Dupilumab in the OVA-induced allergic asthma model
(A) Schematic of the experimental procedure. An OVA-induced allergic asthma model was established in 6-week-old female huIL4/huIL4RA mice and treated with varying doses of Dupilumab.
(B) Growth curves indicated no significant differences in body weight among the groups during the experimental period.
(C–E) FACS analysis revealed that OVA stimulation significantly increased the infiltration of CD45⁺ immune cells and eosinophils in bronchoalveolar lavage fluid (BALF). Dupilumab treatment effectively attenuated this cellular infiltration in a dose-dependent manner, further reducing the proportion of eosinophils among CD45⁺ cells.
(F–H) ELISA results demonstrated that OVA stimulation significantly elevated the levels of hIL-4, mCCL17 (TARC) in BALF, and total serum IgE. These markers were significantly reduced following Dupilumab treatment.
Collectively, these findings indicate that OVA-induced huIL4/huIL4RA mice exhibit a typical Th2-type airway inflammation phenotype and respond effectively to Dupilumab, making this model suitable for pharmacodynamics (PD) evaluation of drugs targeting the IL-4/IL-4RA pathway. (Data are presented as Mean±SEM, n=3–5. One-way ANOVA: *p<0.05, **p<0.01, ***p<0.001.)

Figure 6. Efficacy of Dupilumab treatment on airway inflammation in huIL4/huIL4RA mice in the OVA-induced allergic asthma model (6-week-old female mice).
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
